Parenteral Drugs (India) Limited

PDPL

INE904D01019

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:51 2023-08-21 am EDT			5-day change	1st Jan Change
3.39 ^INR	+4.63%		-.--%	-.--%

2023	PSBs Reportedly Shelve Deal to Sell Drug Company Loans to NARCL	CI
2023	NARCL Reportedly Offers to Buy INR 11,000 million Loans of Parenteral Drugs	CI

Parenteral Drugs India Limited Reports Earnings Results for the First Quarter Ended June 30, 2020

August 25, 2020 at 04:43 am EDT

Parenteral Drugs India Limited announced earnings results for the first quarter ended June 30, 2020. For the first quarter, the company announced total revenue was INR 29.307 million compared to INR 87.290 million a year ago. Net loss was INR 322.185 million compared to INR 276.861 million a year ago. Basic loss per share was INR 10.81 compared to INR 9.29 a year ago.

Latest news about Parenteral Drugs (India) Limited

PSBs Reportedly Shelve Deal to Sell Drug Company Loans to NARCL	23-07-03	CI
NARCL Reportedly Offers to Buy INR 11,000 million Loans of Parenteral Drugs	23-05-10	CI
Parenteral Drugs Limited Announces Resignation of Pooja Choukse as Company Secretary	22-08-10	CI
Parenteral Drugs Limited Announces Director Changes	22-08-09	CI
Parenteral Drugs Limited Appoints Smt. Chhaya Gupta as an Independent Director	22-03-01	CI
Parenteral Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-14	CI
Parenteral Drugs Limited Announces Change in Directorate	22-02-02	CI
Parenteral Drugs Limited Announces Executive Changes	22-02-02	CI
Parenteral Drugs Limited Announces Change in Terms of One Time Loan Settlement Proposal	22-01-06	CI
Parenteral Drugs Limited Announces Resignation of Suruchi Maheshwari as Company Secretary and Compliance Officer	22-01-01	CI
Parenteral Drugs Limited Announces Resignation of Deepali Garhewal as Director	21-11-30	CI
Parenteral Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-12	CI
Parenteral Drugs India Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	21-08-10	CI
Parenteral Drugs India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	21-06-30	CI
Parenteral Drugs Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	21-02-12	CI
Parenteral Drugs Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	20-11-10	CI
Parenteral Drugs India Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	20-08-25	CI
Parenteral Drugs India Limited Reports Earnings Results for the Third Quarter Ended December 31, 2019	20-02-12	CI
Parenteral Drugs Limited Reports Unaudited Standalone and Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2019	19-11-12	CI
Parenteral Drugs India Limited Reports Earnings Results for the First Quarter Ended June 30, 2019	19-08-06	CI
Parenteral Drugs Limited Announces Disqualification Vinod Kumar Gupta as Director	19-06-11	CI
Parenteral Drugs India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2019	19-05-30	CI
Parenteral Drugs Limited Appoints Vinod Kumar Gupta as Chief Financial Officer	19-04-23	CI
Parenteral Drugs Limited Announces the Resignation of Mr. Balkrishna Vinayak Chaubal from the Post of Nominee Director	19-04-20	CI
Parenteral Drugs Limited Announces Cessation of Vinod Kumar Gupta as Managing Director	19-02-27	CI

Chart Parenteral Drugs (India) Limited

Duration

Period

More charts

Company Profile

Parenteral Drugs (India) Limited is engaged in the manufacturing of pharmaceutical products. It also manufactures intravenous (IV) infusion, inhalation, and veterinary infusion. It offers products in various categories, including IV fluids, oncology, anesthesia and exports. Its IV Fluids include Carbohydrated and Electrolytes, such as Dextrose IP 5%, 10%, 20%, Dextrose IP 25% , and Ringer Lactate IP; Diuretics, such as Mannitol 10%, 20% and Manidex (Mannitol 10% with Glycerine 10%); Dialysis and Irrigation Solution, such as Peritoneal Dialysis Solution with 1.7% Dextrose and 1.5% Glycine; Anti-infective and Anti-fungal, such as Ciprofloxacin 200mg and Metronidazole 500mg and others , such as Tamolgan (Paracetamol 1000mg) and PD-Invert (10% Invert Sugar). Its Oncology product mix includes 5 FU-PAR and BAZIPAR. Its Anesthesia product mix includes Sevoplan (Sevoflurane 100/250ml) and Isoplan (Isoflurane 100/250ml).

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PARENTERAL DRUGS (INDIA) LIMITED	-.--%	1.21M
ELI LILLY AND COMPANY	+34.35%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-3.49%	372B
MERCK & CO., INC.	+20.15%	332B
ABBVIE INC.	+6.19%	294B
ASTRAZENECA PLC	+14.11%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+9.21%	168B

Other Pharmaceuticals